Eagle Pharmaceuticals Inc (EGRX) was Reiterated by Mizuho to “Neutral” according to the research note released today. The brokerage firm has raised the Price Target to $ 65 from a previous price target of $47 . Mizuho advised their investors in a research report released on Aug 16, 2016.
Many Wall Street Analysts have commented on Eagle Pharmaceuticals Inc. Shares were Downgraded by Mizuho on Jun 20, 2016 to ” Neutral” and Lowered the Price Target to $ 47 from a previous price target of $66 .
On the company’s financial health, Eagle Pharmaceuticals Inc reported $0.80 EPS for the quarter, beating the analyst consensus estimate by $ 0.09 according to the earnings call on Aug 9, 2016. Analyst had a consensus of $0.71. The company had revenue of $40.90 million for the quarter, compared to analysts expectations of $39.20 million. The company’s revenue was up 581.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.53 EPS.
Eagle Pharmaceuticals Inc closed down -1.39 points or -2.24% at $60.66 with 3,84,438 shares getting traded on Monday. Post opening the session at $62.55, the shares hit an intraday low of $60.02 and an intraday high of $62.72 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
In a different news, on Apr 5, 2016, Scott Tarriff (President and CEO) sold 30,765 shares at $40.63 per share price. According to the SEC, on Mar 16, 2016, Michael Graves (director) purchased 1,000 shares at $56.73 per share price. On Dec 23, 2015, Sander A Flaum (director) sold 13,025 shares at $67.88 per share price, according to the Form-4 filing with the securities and exchange commission.
Eagle Pharmaceuticals Inc. (Eagle Pharmaceuticals) is a specialty pharmaceutical company. The Company focused on developing and commercializing injectable products. It develops products that address the shortcomings as identified by physicians pharmacists and other stakeholders of existing commercially injectable products. Its two most advanced product candidates are EP-3101 (bendamustine RTD) an intravenous version of the chemotherapeutic agent that is marketed by Teva under the brand name Treanda and Ryanodex (dantrolene for MH) and an intravenous version of an approved treatment for malignant hyperthermia. Its products include EP-3101 EP-3102 Ryanodex EP-4104 EP-6101 EP-5101 EP-1101 and EP-2101. Teva markets its bendamustine product under the trade name Treanda.